a mainstay of medical therapy for the last two millennia. Nowadays, prescription laxatives are usually reserved for treating severe constipation or as a bowel washout. 1 However, over-thecounter laxatives are freely available and sold in huge quantities. 2 Chronic laxative use is undoubtedly common and, if excessive, may cause symptoms, the most common being diarrhoea, abdominal pain, general weakness, weight loss, nausea and vomiting. 3 The only sign suggestive of chronic laxative abuse is melanosis coli, a rectal pigmentation that is associated with longterm ingestion of anthraquinone laxatives. 4 Factitious diarrhoea due to surreptitious laxative abuse (SLA) with phenolphthalein was initially detected fortuitously during alkalinization of faecal fat for analysis. 5 Since then, it has been increasingly recognized as an important medical and diagnostic problem. 6±8 However, the diagnosis may often be overlooked, resulting in extensive investigations. 8, 9 These investigations are often normal, leading to an erroneous diagnosis of irritable bowel syndrome or, since chronic laxative ingestion may cause mucosal in¯ammation, 6, 8 in¯ammatory bowel disease. Such patients may have a form of Munchausen's syndrome 10 and are often women with emotional, psychiatric or social dif®culties, who are otherwise healthy. A variant of SLA known as Munchausen syndrome by proxy 11 or Polle syndrome 12 has been reported in several young children whose diarrhoea was caused deliberately by a parent. 12±19 Various reports have estimated the prevalence of SLA to be between 4% and 26% of patients with chronic diarrhoea (Table 1) . 6, 8, 9, 20, 21 This variation probably re¯ects differences in patient selection and the poor sensitivity of some detection methods. There are no data on the prevalence of laxative abuse by proxy, although (judging from the few case reports) it appears to be very rare. However, the fact that three of these cases were reported from a single centre in which phenolphthalein was the only laxative screened 14 suggests that the prevalence may be underestimated. In addition, only 50% of children's hospitals in the UK generate laxative screening requests. 22 Laxatives are quite widely abused, both to control body weight and by patients with eating disorders. In one review of 31 reports of patients with bulimia, the combined prevalence of laxative use was about 15%. 23 However, in this group the abuse is not usually secretive and is unlikely to raise medical or diagnostic issues.
TYPES OF ABUSED LAXATIVES AND THEIR METABOLISM
In SLA, laxatives are probably bought over-thecounter in high street pharmacies or health food shops ( Table 2) . 24±26 The most widely used and abused are colonic stimulants, comprising diphenylmethane compounds such as phenolphthalein and bisacodyl, and anthraquinone compounds such as senna, aloin, cascara, frangula and other plant-derived extracts.
Of the colonic stimulant laxatives, phenolphthalein has been abused most commonly. 6, 21, 27 This will change, however, because phenolphthalein has been reclassi®ed by the Food and Drug Administration in the USA 28 (as a result of carcinogenicity in animals fed high doses) and direct sales to the public are now banned. The Medicines Control Agency in the UK made a similar ruling in September 1998 and phenolphthalein has now been withdrawn as an over-the-counter medicine. 29 Several marketleading laxatives previously containing phenolphthalein have been reformulated using sennosides. 30 As a consequence, phenolphthalein abuse will undoubtedly decrease whereas abuse of anthraquinones and bisacodyl will probably rise. Oxyphenisatin was previously withdrawn from the UK market because of hepatotoxicity, and danthron is only available on a restricted basis by prescription. Of the other laxatives listed in Table 2 , only magnesium and sulphate have previously been implicated in laxative abuse.
Diphenylmethane laxatives are readily absorbed and are metabolized in the liver, with deacetylation and glucuronidation of bisacodyl, and sulphation and glucuronidation of phenolphthalein. The glucuronide conjugates so formed are excreted in bile but are poorly absorbed from the intestine and so pass to the colon where they are deconjugated to their active form by bacterial enzymes. Absorption from the colon completes an enterohepatic circulation, and excretion is ultimately in urine (mainly as glucuronides) or in faeces as metabolites. Anthraquinone laxatives are glycosides and, being resistant to digestion, reach the colon where bacterial b-glucuronidases release the active aglycones. 31 The metabolites of senna, aloe, cascara and frangula are rhein, 32 aloeemodin 27 and/or emodin, which are absorbed from the colon and excreted mainly in the urine.
Colonic stimulant laxatives usually act locally rather than systemically, but suf®cient is absorbed to allow their detection in urine. Studies in rats indicate that excretion of anthraquinones is predominantly renal. 33 Data are lacking on the time taken for excretion of laxatives, although phenolphthalein is present in 
METHODS FOR ANALYSIS OF LAXATIVES pH manipulation
Early methods for detecting colonic stimulant laxatives were based on their pH-indicating properties. 36, 37 Speci®cally, phenolphthalein turns a strong violet colour when urine is alkalinized, whereas urinary anthraquinones show a less obvious colour change after solvent extraction and alkalinization. This approach is currently in use in some UK laboratories although the effectiveness of the method has not been evaluated. In a survey in which three urine samples containing laxatives were sent to UK laboratories for analysis, a high false negative rate (84%) was found. 22
Thin-layer chromatography
Thin-layer chromatography (TLC) is a more effective method for detecting colonic stimulant laxatives in urine, and a number of methods have been described. 32,35,38±40 Laxatives are initially deconjugated using glucuronidase, either overnight at room temperature or for 2 h at 60 Ê C. 39 They are extracted into a nonpolar solvent (usually chloroform±isopropanol, 9:1) or by solid-phase extraction using a C18 column. 40 After TLC separation the plate is sprayed with a strong alkali. Anthraquinone metabolites are visualized as an orange/pink/ purple colour and phenolophthalein turns a vivid violet. Bisacodyl metabolites are visible as blue-grey spots only after heating the plate. Rhein is an excreted metabolite of all anthraquinone laxatives with the exception of frangula, which is metabolized to emodin (Duncan, unpublished data). Both rhein and emodin should therefore be run as standards (available commercially from Sigma Chemical Co., Poole, UK, and Aldrich Chemical Co., Gillingham, UK), together with bisacodyl metabolite, which must be synthesized, 39 and phenolphthalein. Picosulphate, the disulphuric acid ester of bisacodyl, is not detectable by most TLC methods. TLC gave better results than simple alkalinization in the UK survey but still produced a false negative rate of 46% and a misidenti®cation rate of 8%. 22 In a questionnaire survey, no speci®c method-related reason for this poor performance was apparent, except for the ®nding that two laboratories that failed to identify bisacodyl did not heat the plate after alkalinization (Duncan, unpublished data).
Gas chromatography±mass spectrometry
A gas chromatography±mass spectrometry (GC±MS) method has been published for desacetyl bisacodyl, phenolphthalein and the parent compound dioxyanthraquinone. 41 After solid-phase extraction and trimethylsilylation, laxatives are detectable at levels of less than 0´1 mg/mL. 41 A simpler ion-chromatography method has been described but was not evaluated for anthraquinones. 42 No GC±MS method is routinely available in the UK, although a system is currently being developed and will be displayed on the AssayFinder website under`laxative con®rmation' when available (http://assay®nder. jt2.ox.ac.uk).
Analysis of faecal magnesium
A number of cases of magnesium laxative abuse have been described. 8,15,20,21,43±46 Although this may result in modestly increased plasma and urinary magnesium concentrations, the diagnosis can be made reliably only by demonstrating an increase in faecal magnesium concentration. 15, 38 The simplest and most widely employed approach is measurement of magnesium concentrations in faecal water. 38, 43, 44 The analysis is easily performed using atomic absorption spectrometry at 265 nm after dilution with 5% lanthanum chloride. 38 In control patients with diarrhoea, the faecal magnesium concentration is usually very low. However, there is some disparity between suggested upper limits of magnesium in faecal water: cut-off concentrations of 11´3, 44 20, 43 30 38 and 45´2 15 mmol/L have all been suggested. The inclusion of patients with steatorrhoea in the reference population may partly explain the higher ®gures. 15, 38 The cut-off ®gure of 45´2 mmol/L was set deliberately high to enhance speci®city (3 SD above a mean of 14´9 mmol/L, rather than the more conventional 2 SD, which would have given an upper limit of normal of 35 mmol/L). 15 In this study, all cases of diarrhoea that were not magnesium-induced had soluble faecal magnesium concentrations below 30 mmol/L.
Magnesium concentration may also be related to wet weight of faeces. Concentrations exceeding 100 mmol/kg are suggestive of magnesium abuse, 38,47 but the results from control patients overlap those from diarrhoea patients. 38 Fine et al. 15 suggested a daily faecal magnesium output above 14´6 mmol as a cut-off. However, in addition to dif®culties in obtaining accurately timed faecal samples, six of 21 high results in patients with chronic diarrhoea were falsely positive. By contrast, a child given magnesium by her mother had a magnesium concentration in faecal water of only 31 mmol/L but an unequivocally raised faecal output of 76 mmol/day.
It is important to ensure that the patient has not ingested large amounts of magnesium unwittingly. For example, in 359 chronic diarrhoea patients, 15 had raised faecal magnesium outputs, most of whom had innocently ingested magnesium-containing antacids or multivitamins. 15 The diarrhoea usually ceased after withdrawal of the oral source.
Although there are relatively few reported cases of magnesium laxative abuse, it is likely that this is partly due to the infrequency of faecal magnesium measurements. For example, only 15% of the laboratories in the UK that provide a laxative screening service measure faecal magnesium (Duncan, unpublished data).
Faecal osmotic gap measurement
Estimation of the faecal osmotic gap is a simple but infrequently requested 22 investigation that may be useful in the investigation of chronic idiopathic diarrhoea. 21, 48 Sodium and potassium concentrations are measured in faecal water and their sum doubled to account for anions. This ®gure is subtracted from an assumed osmolality of 290 mosmol/kg or from the measured plasma osmolality. The assumed ®gure of 290 mosmol/ kg gives a close approximation to intracolonic 49 osmolality and should be used in preference to the measured faecal osmolality, 48, 50 which increases after defaecation because of continuing bacterial fermentation.
The faecal osmotic gap is high in osmotic diarrhoea due to raised luminal concentrations of unabsorbed molecules such as magnesium or malabsorbed carbohydrates. It is low in secretory diarrhoea associated with colonic stimulant laxatives, hormonal causes [e.g. vasoactive intestinal peptide-producing tumour (VIPoma), carcinoid syndrome] and some gastrointestinal infections (e.g. cholera). A value of 50 mosmol/ kg has been proposed as a suitable cut-off. 48 In diarrhoea experimentally induced by various laxatives, the faecal osmotic gap in 33 samples from 22 subjects with phenolphthaleininduced diarrhoea was less than 50 mosmol/kg, and in 36 samples from 12 subjects with magnesium-induced diarrhoea faecal osmotic gaps exceeded 140 mosmol/kg and were usually over 200 mosmol/kg. 48 Figure 1 shows faecal osmotic gaps in diarrhoea caused by colonic stimulant laxatives and magnesium. High results (over 50 mosmol/kg) make colonic stimulant laxative abuse unlikely and should prompt the measurement of faecal magnesium, whereas values less than 100 mosmol/kg effectively exclude magnesium-induced diarrhoea and should encourage a urinary laxative screen to be performed. Although this application of the faecal osmotic gap requires a full prospective evaluation, it is a simple approach which has proved clinically useful in my experience.
The faecal osmotic gap may, rarely, give misleading results. Simultaneous ingestion of 20, 37 were omitted because the measured faecal osmolality was low, indicating possible factitious addition of water to the stool.
an osmotic and a colonic laxative may lead to an intermediate faecal osmotic gap. 8, 15 Secondly, dilution of the faecal collection with water in order to mislead the clinician may cause low values. 21, 45, 51 Measurement of faecal osmolality may be useful when this is suspected. Finally, a misleading faecal osmotic gap may arise because its calculation is based on measurement of faecal cations only, presupposing that unabsorbed faecal anions do not cause diarrhoea. Consequently, osmotic diarrhoea caused by ingestion of sulphate will produce a low faecal osmotic gap when the accompanying cation is sodium. 48
Detection of other laxatives
To my knowledge, no case of laxative abuse involving sodium picosulphate, phosphate or lactulose has been reported, and only one case of sulphate ingestion has been reported, in which a 6-year-old boy was given Glauber's salts (sodium sulphate) by his mother. 17 Consequently, these laxatives are not usually included in a routine laxative screen, although colourimetric methods for faecal sulphate 52 and phosphate 21, 53 have been described. Suggested upper limits of normal for faecal phosphate concentration and output are 33 mmol/L and 15 mmol/day, respectively. 53 Colonic bacteria metabolize lactulose to short-chain fatty acids, which are common intra-colonic constituents, and so lactulose abuse cannot be diagnosed directly. However, useful pointers towards lactulose-induced diarrhoea (and carbohydrate malabsorption in general) are a high faecal osmotic gap, usually in excess of 100 mosmol/kg, and a faecal pH of less than 5´3. 48 Failure to search for these laxatives may result in missed diagnoses, but this must be balanced against the improbability of detecting a case. For example, in one study conducted over a 6-year period in which all chronic diarrhoea patients were screened for faecal phosphate and sulphate, no cases were found. 21
SAMPLES FOR ANALYSIS
Colonic stimulant laxatives are excreted in both urine and faeces, but urine gives better results for screening purposes. 35 Laxatives are stable in urine over an extended time period and so no special collection is necessary. A random urine sample is required and it has been suggested that the chance of missing laxative abuse is minimized by collecting a ®rst morning urine sample. 40 To maximize the chance of detecting intermittent 3, 8 abuse of laxatives, it may be worthwhile to screen multiple urine samples collected over several days. 36, 40 An alternative approach is to screen a single urine sample when the patient is known to have diarrhoea.
Faecal analysis is useful for detecting ingestion of magnesium-containing and other osmotically active laxatives. Faecal water for measurement of magnesium and the osmotic gap is obtained either by centrifugation or by ®ltration. A ®ltrate can easily be prepared using commercially available ®ltration cones 54 (Centrio membrane cones; Millipore UK Ltd, Watford, UK) and may be preferable in order to minimize the risk of particulate matter blocking analytical instrumentation. Another bene®t of preparing the sample by ®ltration is an increased yield of faecal water when the faecal sample is loose or semi-formed rather than liquid.
Sodium and potassium concentrations are stable in faecal water, but magnesium concentrations may increase. 38 This can be minimized by rapid delivery of the sample to the laboratory and storage in a refrigerator. There is no consistency in the literature on whether a timed faecal collection or a random sample should be used. Local experience has shown that there are potentially large changes in the faecal osmotic gap in consecutive faecal samples when the diarrhoea is multifactorial in nature. However, when diarrhoea is caused by a single pathogenic process, the faecal osmotic gap measured in consecutive samples gives consistent results. For this reason, we measure faecal magnesium concentration and faecal osmotic gap in a random stool sample that is collected when the patient is known to have loose bowel motions.
QUALITY ASSURANCE
A pilot National External Quality Assurance Scheme (NEQAS) for colonic stimulant laxatives in urine was established in the UK in 1996 (Wolfson EQA Laboratory, PO Box 3909, Birmingham, UK). The samples distributed were collections from volunteers who had ingested a single dose of laxative. The urinary concentrations of laxative metabolites were unknown but, given the published sensitivity of methods 35 should have been detectable by TLC, since doses equal to, or exceeding, the maximum recommended dose were taken and in most cases were suf®cient to cause loose motions. Colonic stimulant laxatives were measured by TLC by all those participants who provided information on methodology.
The results of the 2-year pilot are summarized in Table 3 . There was a signi®cant false negative rate for all laxatives, especially anthraquinones and bisacodyl. In view of the better detection rate of phenolphthalein by TLC, the overall false negative rate is likely to rise with the withdrawal of phenolphthalein as an over-the-counter medicine. Of greater concern was the high number of false positive results erroneously indicating laxative abuse; ironically, a denial of laxative ingestion would be consistent with the diagnosis. A patient's denial may test the clinician's con®dence in the laboratory result and so false positive results are particularly damaging to the credibility of the service offered. The validity of two results from this laboratory ± which were unequivocally positive for phenolphthalein and bisacodyl ± was doubted by clinicians who questioned the reliability of the laboratory tests rather than the vehement denial of their patients.
There are large variations in the performance of laboratories in the scheme. Although no laboratory achieved 100% reliability, some approached this ®gure, but in 40% of laboratories the performance was less than 50% reliable. Thus there is a need for work by participating laboratories to improve the sensitivity and speci®city of their methods. To date, the methodologies have not been evaluated and so aspects of the analytical technique, such as the extraction process, solvent system, TLC plates and detection method, have not been optimized. In view of the indifferent overall analytical performance and the importance of avoiding false positive results, it is desirable to have a con®rmation method available for positive results. For this reason, some laboratories run TLC plates in duplicate using different solvent systems.
RECOMMENDATIONS FOR A LAXATIVE SCREENING SERVICE
The main initial prerequisite for making a diagnosis of SLA is a high index of clinical suspicion; 7 this can be tested by performing a chemical laxative screen or searching for laxatives among the patient's belongings. 10, 55, 56 Although the latter action may be justi®ed, there are ethical and legal implications, 7,57 the search has to be done while the patient is in hospital and a negative search does not exclude laxative abuse. It has been advised that a search be carried out in the presence of two suitable witnesses to safeguard against allegations of theft, and, if laxatives are found, they should be counted and then recounted a few days later. 55 SLA is best investigated by performing a TLC screen using a single random urine sample collected at a time when the patient is known to have diarrhoea. Whether or not the patient has diarrhoea can be reliably assessed only by examination of a stool sample collected at the same time. If the TLC screen is negative and an accompanying faecal sample is formed, then a repeat screen is advisable when the patient has diarrhoea. Measurement of the faecal osmotic gap on this sample may also be useful, and elevated values (>100 mosmol/kg) should prompt faecal magnesium analysis, the only way that magnesium-induced diarrhoea can be reliably diagnosed.
Given the variable performance of current TLC methods, it is essential that results are validated by internal quality control and good NEQAS performance If the request rate is low, or if there are concerns about the reliability of the service offered, it may be prudent to send samples to an external laboratory where good performance can be demonstrated. Given the potential for false positive results, GC±MS methods should ideally be available to con®rm a positive result. 
CONCLUSION
Despite the increasing general awareness of SLA, it is a diagnosis that is frequently overlooked, 8, 9 leading to unnecessary investigations with concomitant ®nancial implications. SLA requires laboratory investigations before a de®nite diagnosis can be made. Unfortunately, laboratory back-up is often not requested, not available, or unreliable. A reliable laboratory service, either local or supraregional, is essential for ef®cient, effective investigation of chronic idiopathic diarrhoea and appropriate management of patients.
